Study on Subcutaneous Blinatumomab for Treating Acute Lymphoblastic Leukemia (ALL)

Inclusion Criteria

• Age 18 years or older.
• Diagnosed with B-precursor Acute Lymphoblastic Leukemia (ALL) that:
  • Did not respond to initial treatment or at least one additional treatment, OR
  • Has returned after being treated, whether it's the first, second, third, or later relapse.
• More than 5% cancer cells in the bone marrow, unless the disease is only outside the bone marrow and not in the central nervous system.
• Good overall health with a performance status score of 2 or less.
• Patients with a specific type of ALL (B Cell ALL Ph+) who cannot tolerate or did not respond to previous treatments with tyrosine kinase inhibitors (TKIs) are eligible.

Exclusion Criteria

• Active leukemia in the central nervous system (CNS) or signs of CNS leukemia.
• History of serious brain or nervous system conditions, such as seizures, stroke, or severe brain injuries.
• Disease only outside the bone marrow.
• Active or uncontrolled infections or other conditions that could worsen with treatment.
• Testicular leukemia.
• History of other cancers (with some exceptions) within the last 3 years.
• Recent stem cell transplant within 12 weeks before starting the study treatment.
• Recent cancer treatment, including chemotherapy within 2 weeks or immunotherapy within 4 weeks before starting the study treatment.
• Participation in another clinical trial within the last 30 days.
• Abnormal lab test results at screening.
• Women who are breastfeeding or plan to breastfeed during treatment and for 96 hours after the last dose.